Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2025 08:30 ET | Source: Surrozen, Inc.

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway
May 09, 2025 16:05 ET | Source: Surrozen, Inc.

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

Surrozen Reports First Quarter 2025 Financial Results and Business Update
March 31, 2025 16:05 ET | Source: Surrozen, Inc.

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates
March 24, 2025 09:00 ET | Source: Surrozen, Inc.

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

SRZN Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Disease
November 06, 2024 16:30 ET | Source: Surrozen, Inc.

Surrozen to Present at Upcoming Healthcare Investor Conferences

Surrozen to Present at Upcoming Healthcare Investor Conferences in November 2024
November 06, 2024 09:00 ET | Source: Surrozen, Inc.

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Surrozen Provides Third Quarter 2024 Financial Results and Business Update
November 04, 2024 08:30 ET | Source: Surrozen, Inc.

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary FIbrosis
September 24, 2024 08:30 ET | Source: Surrozen, Inc.

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
August 12, 2024 16:05 ET | Source: Surrozen, Inc.

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Surrozen Provides Second Quarter 2024 Financial Results and Business Update
June 12, 2024 08:30 ET | Source: Surrozen, Inc.

Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Surrozen Publishes Study in eLife Demonstrating the Promise of the SWEETS Platform, a Unique TPD Technology, to Further Enhance Wnt Signaling

Next Page keyboard_arrow_right